In contrast to its broadly oncogenic activity in HCC, ICC, BCa and glioma, accumulating evidence indicates that m7G/METTL1 can exert tumour‐suppressive effects in lung cancer, colon cancer, and, in defined contexts, breast cancer (Table 2 and Figure 3). Here, METTL1 is linked to breast cancer.